Cardiac Magnetic Resonance in Stable Coronary Artery Disease: Added Prognostic Value to Conventional Risk Profiling

Table 1

Baseline characteristics and differences between patients without and with primary outcome. (all-cause mortality).

	All patients	Event free	With events	P Value
	(n=465)	(n=415)	(n=50)
ANTHROPOMETRY
Age (years)	63 ± 11	63 ± 11	67 ± 10	0.006
Male sex	372 (80%)	334 (81%)	38 (76%)	0.454
Body mass index (kg/m2)	26 ± 4	26 ± 4	26 ± 5	0.088
CAD RISK FACTORS
Family history of CAD	201 (43%)	183 (44%)	18 (38%)	0.454
Smoking	283 (61%)	245 (59%)	38 (76%)	0.018
Diabetes	88 (19%)	75 (18%)	13 (26%)	0.170
Hypertension	267 (57%)	238 (57%)	29 (57%)	0.417
Hypercholesterolemia	271 (58%)	241 (58%)	30 (60%)	0.763
No. of CV risk factors	2.4 ± 1.2	2.4 ± 1.2	2.6 ± 1.0	0.358
CLINIC HISTORY
Previous CAD diagnosis	398 (86%)	350 (84%)	48 (96%)	0.027
Previous myocardial infarction	298 (64%)	257 (62%)	41 (82%)	0.005
LM or 3-vessel CAD	165 (35%)	144 (35%)	21 (42%)	0.292
NYHA classification (III class)	15 (3%)	11 (3%)	4 (8%)	0.111
Revascularization in the follow-up	112 (24%)	106 (26%)	6 (12%)	0.032
PHARMACOLOGICAL THERAPY
β-blockers	361 (78%)	321 (78%)	40 (80%)	0.692
Ca^++-antagonist	97 (21%)	85 (21%)	12 (24%)	0.563
Nitrates	184 (40%)	161 (39%)	23 (46%)	0.325
Loop diuretics	146 (31%)	122 (29%)	24 (48%)	0.007
Aldosterone antagonist	54 (12%)	44 (11%)	10 (20%)	0.050
ACE-inhibitors/ARB	369 (79%)	330 (80%)	39 (78%)	0.802
ASA	396 (85%)	351 (85%)	45 (90%)	0.308
Statins	355 (76%)	317 (76%)	38 (76%)	0.952
Anticoagulant use	28 (6%)	22 (5%)	6 (12%)	0.117
ECG
Heart rate (bpm)	64 ± 12	64 ± 11	70 ± 14	<0.001
Non sinus rhythm	14 (3%)	11 (3%)	3 (6%)	0.317
QRS duration (msec)	104 ± 19	103 ± 18	111 ± 24	0.021
QTc interval (msec)	423 ± 31	421 ± 31	436 ± 33	0.002
LV hypertrophy	66 (14%)	57 (14%)	9 (18%)	0.440
LBBB	55 (12%)	43 (10%)	12 (24%)	0.005
RBBB	59 (13%)	51 (12%)	8 (16%)	0.486
ST segment depression	28 (6%)	24 (6%)	4 (8%)	0.758
Negative T waves	217 (47%)	186 (45%)	31 (62%)	0.021
Q waves	178 (38%)	158 (38%)	20 (41%)	0.660
ECHOCARDIOGRAPHY
LVEDV (ml/m^2)	60 ± 30	58 ± 29	72 ± 29	0.006
LVESV (ml/m^2)	29 ± 17	27 ± 15	44 ± 26	<0.001
LVEF (%)	53 ± 13	54 ± 12	43 ± 14	<0.001
LVWMSI	1.4 ± 0.4	1.3 ± 0.4	1.7 ± 0.5	<0.001
LV mass (g)	197 ± 64	195 ± 61	220 ± 86	0.053
LV diastolic dysfunction (≥pseudo-normal)	42 (9%)	34 (8%)	8 (16%)	0.119
Mitral regurgitation (≥ moderate)	65 (14%)	51 (12%)	14 (27%)	0.006
Pulmonary hypertension (sPAP>35 mmHg)	34 (7%)	27 (8%)	7 (14%)	0.102
RVIT dilatation (>40 mm)	30 (7%)	27 (7%)	3 (6%)	1.000
RV dysfunction (TAPSE<15 mm)	35 (8%)	28 (7%)	7 (14%)	0.122
CARDIAC MAGNETIC RESONANCE
CMR LVEF (%)	54 ± 15	56 ± 14	43 ± 18	<0.001
CMR LV mass (g)	153 ± 40	151 ± 37	174 ± 55	0.006
CMR LVEDV (ml/m^2)	70 ± 46	69 ± 47	85 ± 37	0.014
CMR LGE (% of LV mass)	11 ± 13	10 ± 12	19 ± 18	<0.001
CMR myocardial stress induced perfusion abnormality	82 (18%)	73 (18%)	9 (18%)	0.943

CAD = coronary artery disease; CV = cardiovascular; LM = left main; NYHA = New York heart association; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; QTc = corrected QT; LBBB = left bundle branch block; RBBB = right bundle branch block; LVEDV = left ventricle end diastolic volume, LVESV = left ventricle end systolic volume; LVEF = left ventricle ejection fraction; LVWMSI = left ventricle wall motion score index; TAPSE = tricuspid annular plane systolic excursion; RVIT = right ventricle inflow tract; CMR = cardiac magnetic resonance; LGE = late gadolinium enhancement.
Pearson χ² or Fisher's exact test for categorical data; Student's t-test or Mann–Whitney for continuous data.